Anemia in diabetic nephropathy: prevalence, clinical and pathophysiological aspects
- Authors: Shestakova MV1, Martynov SA1, Il'in AV1, Kniazeva AP1, Shamkhalova MS.1, Trubitsyna IP1
-
Affiliations:
- ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
- Issue: Vol 80, No 6 (2008)
- Pages: 41-47
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/30187
- ID: 30187
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
M V Shestakova
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
S A Martynov
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
A V Il'in
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
A P Kniazeva
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
M Sh Shamkhalova
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
I P Trubitsyna
ФГУ Эндокринологический научный центр Росмедтехнологий, Москва
References
- King Н., Aubert R. Е., Herman W. Н. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabet. Care 1998; 21: 1414-1431.
- Дедов И. И., Шестакова М. В. Сахарный диабет: Руководство для врачей. М.: Универсум Паблишинг; 2003.
- Дедов И. И., Шестакова М. В. Диабетическая нефропатия. М.: Универсум Паблишинг; 2000.
- USRDS 2007 Annual Data Report, volume I. Atlas of chronic kidney disease and end-stage renal disease in United States. http://www.usrds.org/
- Thomas M., MacIsaac J., Tsalamandris C. et al. Anemia in patients with type 1 diabetes. J. Clin. Endocrinol. Metab. 2004; 89 (9): 4359-4363.
- Thomas M., MacIsaac J., Tsalamandris C. et al. The burden of anemia in type 2 diabetes and role of nephropathy: a cross-sectional audit. Nephrol. Dial. Transplant. 2004; 19: 1792-1797.
- El-Achkar Т. M., Ohmit S. E., McCullough P. A. et al. Higher prevalence of anemia with diabetes mellitus in moderate kidney insufficiency: The Kidney Early Evaluation Program. Kidney Int. 2005; 67: 1483-1488.
- Thomas M., MacIsaac R. J., Power D., Jerums G. Unrecognized anemia in patients with diabetes. Diabet. Care 2003; 26 (4): 1164-1169.
- Broon J. Anemia in diabetic renal disease: and underestimated risk factor. Acta Diabetol. 2002; 39: S2.
- Stevens P. E., O'Donoghue J., Lameire N. R. Anemia in patients with diabetes: unrecognized, undetected and untreated? Curr. Med. Res. Opin. 2003; 19 (5): 395-401.
- Mohanram A., Zhang Z., Shaninfar S. et al. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int. 2004; 66: 1131-1138.
- Thomas M. Anemia in diabetes: marker of mediator of microvascular disease. Nat. Clin. Pract. Nephrol. 2007; 1 (3): 20-30.
- National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation classification and stratification. Am. J. Kidney Dis. 2002; 39 (suppl. 1); S1- S266.
- Cockroft D. W., Gault M. H. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
- World Health Organization. Nutritional anemia: Report of WHO Scientific Group. Geneva; 1968.
- National Kidney Foundation: K/DOQI clinical practice guidelines and clinical practice recommendations for anemia of chronic kidney disease. Am. J. Kidney Dis. 2006; 47 (suppl. 3): S1-S145.
- Macdougall I. C., Eckard K-U., Locatelli F. Latest US DOQI anemia guidelines update - what are the implications for Europe? Nephrol. Dial. Transplant. 2007; 22: 2738-2742.
- Шестакова M. В., Мартынов С. А. Анемия при диабетической нефропатии: прогностическое значение, диагностика и лечение. Consilium Medicum 2006; 9: 39-43.
- Шестакова М. В., Мартынов С. А. Диабетическая нефропатия: все ли факторы риска мы учитываем? Сахар. диабет 2006; 4: 29-33.
- Шестакова М. В., Мартынов С. А. Анемия при диабетической нефропатии: диагностика и лечение. М.; 2007.
- White К. Е., Marshall S. М., Bilous W. Are glomerular volume differences between type 1 and type 2 diabetic patients pathologically significant? Diabetologia 2007; 50 (5): 906-912.
- Lorber D., Reddan D. Clinical characteristics of chronic kidney disease patients with and without diabetes: a subanalysis of the PAERI study. Clin. Nephrol. 2006; 66: 11-16.
- Румянцев А. Г., Морщакова E. Ф., Павлов А. Д. Эритропоэтин в диагностике, профилактике и лечении анемий. М.; 2003.
- Ермоленко В. М., Иващенко М. А. Уремия и эритропоэтин. М.; 2000.
- Artunc Т., Risler A. Serum erythropoietin concentrations and responses to anemia in patients with or without chronic kidney disease. Nephrol. Dial. Transplant. 2007; 22: 2900-2908.
- Bosman D. R., Winkler A. S., Marsden J. T. et al. Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabet. Care 2001; 24 (3): 495-499.
- Fehr Т., Ammann P., Garzoni D. et al. Interpretation of erythropoietin levels in patients with various degrees of renal insufficiency and anemia. Kidney Int. 2004; 66: 1206-1244.
- White К. E., Bilous R. W. Type 2 diabetic patients with nephropathy show structural functional relationships that are similar type 1 disease. J. Am. Soc. Nephrol. 2000; 11: 1667-1673.
- Bosman D. R., Osborne C. A., Marsden J. T. et al. Erythropoietin response to hypoxia in patients with diabetic autonomic neuropathy and non-diabetic chronic renal failure. Diabet. Med. 2002; 19: 65-69.
- Catrina S.-B., Okamoto K., Pereira T. et al. Hyperglycemia regulates hypoxia-inducible factor-1α protein stability and function. Diabetes 2004; 53: 3226-3232.
- Nakao Т., Matsumoto H., Okada T. et al. Influence of erythropoietin treatment on hemoglobin A1c levels in patients with chronic renal failure on heamodialysis. Intern. Med. 1998; 37: 826-830.
- Шестакова M. В., Лепетухин A. E., Кварацхелия M. В., Дедов И. И. Особенности ведения больных сахарным диабетом с терминальной почечной недостаточностью на программном гемодиализе. Тер. арх. 2004; 9: 70-75.
- MacDougall I. The role of ACE inhibitor and angiotensin II receptor blockers in the response to epoetin. Nephrol. Dial. Transplant. 1999; 14: 1836-1841.
- Pratt M. C., Lewis-Barnard N. J., Walker R. J. et al. Effect of angiotensin converting enzyme inhibitors on erythropoietin concentration in healthy volunteers. Br. J. Clin. Pharmacol. 1992; 34: 363-365.
- Stevens P. Optimizing renal anemia management - benefits of early referral and treatment. Nephrol. Dial. Transplant. 2005; 20 (suppl. 8): viii22-viii26.
- Ritz E., Laville M., Bilous R. W. et al. Target level for hemoglobin correction in patients with diabetes and CKD: primary results of the Anemia Correction in Diabetes (ACORD) Study. Am. J. Kidney Dis. 2007; 49: 194-207.
- Singh A. K., Szczech L., Tang K. L. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 2006; 335: 2085-2098.